Melamed A, et al. - Authors intended to gauge the causal effect of increased neoadjuvant chemotherapy (NACT) use on the all-cause mortality in advanced epithelial ovarian cancer. Based on the yielded data, a sizable reduction was brought to light in mortality within three years after diagnosis due to the adoption of NACT for advanced epithelial ovarian cancer in New England and east south central regions.